Recurrent Pancreatic Cancer


Proton Beam Therapy May Improve Outcomes for Esophageal Cancer (January 23, 2017)

Currently a standard treatment for several gastrointestinal cancers (GI) combines the use of chemotherapy and radiation followed by surgical resection. Radiation may be part of the treatment strategy for... Continue Reading

Pancreatic Cancer Cells Find Unique Fuel Sources to Keep from Starving (August 17, 2016)

Pancreatic cancer cells avert starvation in dense tumors by ordering nearby support cells to supply them with an alternative source of nutrition. This is the finding of a study in cancer cells and mice... Continue Reading

MM-398 Receives Fast Track Designation for Advanced Pancreatic Cancer (November 26, 2014)

The U. S. Food and Drug Administration (FDA) has granted MM- 398 plus 5-fluorouracil (5-FU) and leucovorin a Fast Track designation as a second-line treatment for patients with metastatic pancreatic cancer,... Continue Reading

FDA Grants Orphan Drug Designation to Investigational Agent for Pancreatic Cancer (October 7, 2014)

Pancreatic cancer is one of the deadliest forms of cancer. Each year, approximately 43,000 people are diagnosed with pancreatic cancer in the United States and close to 37,000 die from the disease. The... Continue Reading

Simtuzumab Fails to Improve Outcomes in Pancreatic Cancer (September 23, 2014)

Pancreatic cancer is one of the deadliest forms of cancer. Each year, approximately 43,000 people are diagnosed with pancreatic cancer in the United States and close to 37,000 die from the disease. The... Continue Reading

In Advanced Pancreatic Cancer, Eloxatin® with Folinic Acid and Fluorouracil May Improve Survival (July 10, 2014)

In a Phase III study, the addition of the chemotherapy drug Eloxatin® (oxaliplatin) to the chemotherapy regimen of folinic acid and fluorouracil (5-FU) improved outcomes in patients with advanced pancreatic... Continue Reading

Updated Analysis of the MPACT Study in Advanced Pancreatic Cancer Demonstrates Continued Improvement in Survival for Abraxane-based Chemotherapy (July 1, 2014)

A follow up report on the results of the Metastatic Pancreatic Adenocarcinoma Clinical Trial (MPACT) study of Abraxane® (nab-paclitaxel) in combination with Gemzar® (gemcitabine) in previously untreated... Continue Reading

Dual Vaccines Prolong Survival in Metastatic Pancreatic Cancer (February 5, 2014)

The sequential delivery of two vaccines—GVAX and CRS-207—prolonged survival in patients with metastatic pancreatic cancer by about two months, according to the results of a study presented at the 2014... Continue Reading

Abraxane Plus Gemzar Improves Survival in Metastatic Pancreatic Cancer (December 25, 2013)

Abraxane® (nab-paclitaxel) plus Gemzar® (gemcitabine) improved overall and progression-free survival in patients with previously untreated metastatic pancreatic cancer, according to the results of a... Continue Reading

Biological Therapy (November 19, 2013)

Biological therapies are naturally occurring or synthesized substances that direct, facilitate, or enhance the body’s normal immune defenses. Biologic therapies include interferon, interleukins,... Continue Reading

Study Evaluates Whole-brain Radiation Following Surgery or Radiosurgery in Cancer Spread to the Brain (November 16, 2010)

Results from a randomized Phase III study indicate that whole-brain radiation therapy (WBRT) following removal of one to three brain metastases with surgery or radiosurgery does not improve overall survival... Continue Reading

November Is National Pancreatic Cancer Awareness Month (November 5, 2009)

As the month of November brings pancreatic cancer into focus, it’s time to increase public understanding of the disease, including its prevalence, approaches to screening and prevention, treatment options,... Continue Reading

Pancreatic Cancer Care Is Inconsistent (July 21, 2009)

The quality of care for pancreatic cancer varies considerably among hospitals in the United States, according to the results of a study published in the Journal of the National Cancer Institute.[1] Pancreatic... Continue Reading

NCCN Updates Pancreatic Cancer Guidelines (December 12, 2007)

NCCN Updates Pancreatic Cancer Guidelines The National Comprehensive Cancer Network (NCCN), an alliance of 21 leading cancer centers, has updated its guidelines regarding the care of pancreatic cancer... Continue Reading

GEMOX Active in Recurrent Pancreatic Cancer (February 24, 2006)

GEMOX Active in Recurrent Pancreatic Cancer According to a an article recently published in the British Journal of Cancer, the chemotherapy combination consisting of Gemzar® (gemcitabine) plus Eloxatin®... Continue Reading

Pancreatic Cancer Research Map Will Track Researchers, Studies and Funding Opportunities (May 10, 2005)

Pancreatic Cancer Research Map Will Track Researchers, Studies and Funding Opportunities The Pancreatic Cancer Research Map was first launched during Pancreatic Cancer Awareness Month in November 2004.... Continue Reading

Further Evidence that Rubitecan Offers Benefit for Refractory Pancreatic Cancer (December 1, 2003)

Further Evidence that Rubitecan Offers Benefit for Refractory Pancreatic Cancer According to results presented at the Chemotherapy Foundation Symposium XXI, the anticancer agent rubitecan (Orathecin™)... Continue Reading

Raltitrexed and Camptosar® Effective in Recurrent Pancreatic Cancer (April 27, 2003)

Raltitrexed and Camptosar® Effective in Recurrent Pancreatic Cancer According to an article recently published in the British Journal of Cancer, Camptosar® plus raltitrexed demonstrates... Continue Reading

Next Page »

Sign up for the CancerConnect newsletter

Sign up for our newsletter and receive the latest news and updates about specific types of cancer.

  Close |  Please don't show me this again

Facebook Twitter RSS